Navigation Links
CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders
Date:6/16/2009

--Orally Active Enhancer of Human Nerve Growth Factor Has Demonstrated Promising Activity Preclinically--

--Broad Potential Applications Include Neuropathies, Alzheimer's and Huntington's Disease and Others--

RESEARCH TRIANGLE PARK, N.C., June 16 /PRNewswire/ -- CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced that it has obtained the rights to develop and market a novel agent for the prevention and treatment of neuropathies and neurodegenerative disorders. The drug candidate, CXB909, is a small molecule, orally active agent that enhances the effects of nerve growth factor (NGF). CeNeRx intends to initiate a Phase l trial of CXB909 for the treatment of chemotherapy-induced peripheral neuropathy (CIPN) later this year.

"Nerve growth factor has long been of interest as a potential therapy for neuropathies and neurodegenerative diseases, but recombinant NGF lacks key qualities needed for successful CNS drugs," said Dr. Daniel Burch, Executive Vice President of R&D and Chief Medical Officer of CeNeRx. "In preclinical studies, our small molecule agent CXB909 has been shown to increase the action of native NGF, but without the pharmacokinetic and administration challenges of recombinant NGF. Most notably, CXB909 crosses the blood brain barrier, has a long half-life and is orally available. The preclinical data for this agent is very promising, and we look forward to assessing it in the clinic for neuropathic and neurodegenerative conditions that currently have no treatment options."

CXB909 is a downstream enhancer of the effects of nerve growth factor, an endogenously produced neurotrophic factor that is important for the function and survival of several types of neurons. Both Alzheimer's disease and Huntington's disease involve the degeneration of certain neurons, and n
'/>"/>

SOURCE CeNeRx BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
2. CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study
3. CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)
4. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
5. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
7. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
8. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
9. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
10. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
11. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)...irstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM ...f vaccines and therapeutics for the prevention and... that it has retained the services of an internati...EL-SCI,s upcoming Phase III clinical trial in adva...,s lead product candidate, Multikine®. This ...
(Date:12/1/2009)...ire/ -- Sleep Solutions®, Inc. (SSI), the lea...and evaluation of sleep-disordered breathing, toda... its chief executive officer. Hassett was most re...growth from a $250 million healthcare holding comp...opulation health, and its subsequent sale for near...
(Date:12/1/2009)...ewswire/ -- Siemens Hearing Instruments, Inc., (...facturer of hearing instruments, announced its thi...ound Beginnings program. The alliance will be effe... renewed partnership, Siemens is expanding the pro...ruments to both children and young adults, age 23 ...
Breaking Medicine Technology:CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine 2CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine 3Sleep Solutions, Inc. Names Richard Hassett, M.D., New CEO 2Sleep Solutions, Inc. Names Richard Hassett, M.D., New CEO 3Siemens Hearing Instruments Renews Quota Partnership to Give the Gift of Hearing to Children and Young Adults in Need 2Siemens Hearing Instruments Renews Quota Partnership to Give the Gift of Hearing to Children and Young Adults in Need 3Professor receives grant to develop more rapid technology for screening blood samples 60690 1Professor receives grant to develop more rapid technology for screening blood samples 60690 2Cholesterol and Cancer 3A Answers and Some New Questions 60688 1Cholesterol and Cancer 3A Answers and Some New Questions 60688 2Cholesterol and Cancer 3A Answers and Some New Questions 60688 3Cholesterol and Cancer 3A Answers and Some New Questions 60688 4Cholesterol and Cancer 3A Answers and Some New Questions 60688 5Americans Gaining Awareness of COPD 3A Survey 60686 1Americans Gaining Awareness of COPD 3A Survey 60686 2
...ALINE, Mich., Oct. 24 PositiveFriends.com, (http:...network for those affected,by STDs (Sexually Trans...nch into the online social networking and dating s...and features new technology,intended to provide me...,HPV (Human Papilloma Virus) varying levels of pri...
...pdated phase 2 data continue to show encouraging a... Phase 1 data demonstrate tolerability of daily ...FRANCISCO, Oct. 24 Exelixis, Inc.,(Nasdaq: EXEL ... of XL647,an inhibitor of EGFR, HER2 and VEGFR kin...non-small cell lung cancer (NSCLC) patients. The d...
Other Medicine Technology:PositiveFriends.com Launches STD Social Networking Site Balancing Dating with Online Support Features 2Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference 2Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference 3Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference 4Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference 5
(Date:12/1/2009)...Central and South America, study finds , ...rcent of intensive care unit patients worldwide su...g in the hospital, a new study finds. , Researc...8, 2007) on 13,796 patients, aged 18 and older, in...rcent of patients were classified as infected and ...
(Date:12/1/2009)...r 1, 2009)The Clinical Research Building (CRB), at..., has been honored for its sustainability componen... established by the U.S. Green Building Council an...titute (GBCI). LEED is the nation,s preeminent pro... green buildings., "Having a LEED certified build...
(Date:12/1/2009)...LEY, Pa., Dec. 1 Air Pro...he previously announced sale of the assets of its ... the Airthane® and Versathane® tradename...obal polyurethane chemicals producer COIM SpA. ,...turing facility in Paulsboro, N.J. Terms of the ag...
(Date:12/1/2009)...t Safety Authority Encourages Older Persons and He...onsumer Tips Based Upon Authority Data ,, HAR...nety percent of all vaccine preventable deaths occ...ursing homes, according to highlighted studies in ...ecember Patient Safety Advisory . ,, According...
(Date:12/1/2009)...n California are unable to successfully obtain inf...ls despite recent state legislation intended to im.... , Posing as low-income uninsured patients, res...ne-third of the hospitals they approached and the ...se allowed under California law, according to the ...
Breaking Medicine News(10 mins):Health News:Half of ICU Patients Suffer From Infections 2Health News:UM Clinical Research Building awarded prestigious LEED Building Certification 2Health News:Air Products Completes Sale of Polyurethane Pre-Polymers Business to COIM USA 2Health News:Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 2Health News:Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 3Health News:Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 4Health News:Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 5Health News:Hospital price transparancy laws in California fall short, study finds 2
...atens, then it is time for a medicinal tea. // ...dication that something is wrong or at the first s...rberg, spokeswoman for an organisation here that r...d by the hot water. "The classic areas where...
...dengue fever this year so far, which is double the...alth authorities here, two more people have died i... to nine. Out of the 327 cases reported, 127... year the total number of dengue was officially re...
... to produce and sell human stem cells; Roslin Cell...irst ever in Europe,// envisaged to give an impetu... research. The Roslin Cells Center is a brain chil... Donated eggs and embryos will form the basis ...
...le insight for one of the leading mental illnesses...wine has always hogged a fair share of the limelig...rain. A recent study seems to suggest that Red win...ich were portraying alterations in the brain akin ...
...in New Zealand and developed by the UK biotechnolo... in extending lives of lung cancer patients by one...state that it is the first step in the fight again...The efforts to bring down the death rate have fail...
...ays that a mathematical formula can predict the ri...ent accuracy.// Researchers say this will allow do... "Approximately 45 percent of women have differ...risk," said the study's lead author, Margaret Joy ...
Other Medicine News:Health News:Stay Healthy with Herbal Tea 2Health News:Lung Cancer Drug effective in extending lives 2Health News:Formula Predicts Osteoporotic Fracture Risk 2
HDL-Cholesterol Direct Reagent
Ammonia Standard
Proteineer™
...XL-I functions over a wide range of concentration,...re thorough characterization than other methods. I...ive change in the distribution of molecular weight...eity, stoichiometry and self-associating systems. ...
Medicine Products: